RNS Number : 8633C
GSK PLC
12 February 2024
 

GSK plc (the 'Company')

 

Deferred Annual Bonus Plan Awards

On 8 February 2024, the Company granted awards to the Persons Discharging Managerial Responsibilities ('PDMRs') listed below. The awards have been granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') which was approved by shareholders on 4 May 2017.

Executive Directors and other members of the GSK Leadership Team are required to defer part of any bonus earned into Ordinary Shares or American Depositary Shares ('ADS') for three years. Under the terms of the Remuneration Policy approved by shareholders in 2022, Executive Directors are required to defer 50% of bonus equivalent to the first 200% of salary into Ordinary Shares or ADS with any portion in excess of 200% being deferred in full. Other members of the GSK Leadership Team are required to defer 25% of bonus equivalent to the first 170% of salary into Ordinary Shares or ADS with any portion in excess of 170% being deferred in full.

The awards have been granted as restricted awards over ADS for US participants and as nil-cost options over Ordinary Shares for all other participants.

The numbers of Ordinary Shares and ADS shown below are exclusive of dividend reinvestment that will accrue during the deferral period. 

 

 


 

 

 

Transaction notification


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Emma Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.726

147,271






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2024-02-08

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.726

56,190






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2024-02-08

f)

Place of the transaction

 

N/A



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Diana Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.726

37,145






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2024-02-08

f)

Place of the transaction

 

N/A


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.726

37,593






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2024-02-08

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sally Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.726

 

23,289






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2024-02-08

f)

Place of the transaction

 

N/A


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Luke Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.726

69,955






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2024-02-08

f)

Place of the transaction

 

N/A


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Shobie Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

 

ISIN: US37733W2044

b)

Nature of the transaction

Deferred Bonus Award of ADS under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



$42.02

.

17,987






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2024-02-08

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President, Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.726

44,528






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2024-02-08

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.726

53,627






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2024-02-08

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Phil Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.726

29,991






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2024-02-08

f)

Place of the transaction

 

N/A



1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, GSK Global Health

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.726

.

46,391






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2024-02-08

f)

Place of the transaction

 

N/A


1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Tony Wood

b)

Position/status

Chief Scientific Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£16.726

57,148






d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price


e)

Date of the transaction

2024-02-08

f)

Place of the transaction

 

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFIFIEELSEEE
Gsk (LSE:GSK)
過去 株価チャート
から 3 2024 まで 4 2024 Gskのチャートをもっと見るにはこちらをクリック
Gsk (LSE:GSK)
過去 株価チャート
から 4 2023 まで 4 2024 Gskのチャートをもっと見るにはこちらをクリック